Skip to main content
Premium Trial:

Request an Annual Quote

New Joint Venture to Market Diabetes Test, Develop Biomarkers

NEW YORK (GenomeWeb News) – Toyota Tsusho America and Nippon Kayaku have formed a joint venture that will focus on discovering and selling novel biomarkers and biomarker-based tests for diabetes.
The new company, which is called GlycoMark and is located in Winston Salem, NC, and in New York, will sell the GlycoMark diabetes blood test, which the two companies previously commercialized together through a partnership. The GlycoMark test is used to guide management of diabetic patients and for clinical trials on diabetes drugs.
The new company initially will focus its efforts on continuing to commercialize the GlycoMark lab test with partner labs in the US, and it also plans to introduce the test in the European Union. The joint venture also is developing a point-of-care and home-test version of the GlycoMark.
Toyota Tsusho America is a New York, NY-headquartered company with seven operating divisions, including chemicals, metals, machinery, consumer products and others, and Nippon Kayaku is a fine chemicals manufacturer based in Tokyo.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.